Published online before print October 6, 2005, doi: 10.1161/01.ATV.0000189304.32725.bd
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2005 American Heart Association, Inc.
Atherosclerosis and Lipoproteins |
Smoking, Endothelial Function, and Rho-Kinase in Humans
From the Department of Cardiovascular Physiology and Medicine (K.N., C.G., K.N., T.U., D.J., M.Y., Y.H.), Department of Medicine and Molecular Science (K.H., M.K., K.C.), and Department of Clinical Laboratory Medicine (T.O.), Graduate School of Biomedical Sciences, Hiroshima University, Department of Developmental Biology (K.N.), Research Institute for Radiation Biology and Medicine, Japan.
Correspondence to Yukihito Higashi, MD, PhD, FAHA, Department of Cardiovascular Physiology and Medicine, Graduate School of Biomedical Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima 734-8551, Japan. E-mail yhigashi{at}hiroshima-u.ac.jp
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Objective— Smoking is associated with endothelial dysfunction and activated Rho-kinase in vascular smooth muscle cells (VSMCs) in humans. The purpose of this study was to elucidate the relationship between endothelial function and Rho-kinase activity in forearm VSMCs in healthy young men.
Methods and Results— We evaluated the forearm blood flow (FBF) responses to acetylcholine (ACh), fasudil, a Rho-kinase inhibitor, and sodium nitroprusside (SNP) in male smokers (n=10) and nonsmokers (n=14). FBF was measured by using a strain-gauge plethysmography. The vasodilatory effect of ACh was significantly smaller in smokers than that in nonsmokers. The vasodilatory effect of fasudil was significantly greater in smokers than that in nonsmokers. The vasodilatory effects of SNP in the 2 groups were similar. There was a significant correlation between the maximal FBF response to fasudil and that to ACh (r=–0.67; P<0.01). There was no significant correlation between the maximal FBF response to fasudil and that to SNP. The intra-arterial coinfusion of fasudil significantly increased the FBF response to ACh in smokers but not in nonsmokers. There were no significant differences between FBF response to fasudil alone and that in combination with NG-monomethyl-L-arginine in smokers and in nonsmokers. The intra-arterial coinfusion ascorbic acid did not alter the FBF response to fasudil in both groups.
Conclusions— These findings suggest that smoking is involved in not only endothelial dysfunction but also activation of Rho-kinase in VSMCs in forearm circulation, and that there is a significant correlation between endothelial function and Rho-kinase activity in VSMCs.
Smoking is associated with endothelial dysfunction and activated Rho-kinase in vascular smooth muscle cells (VSMCs) in humans. The purpose of this study was to elucidate the relationship between endothelial function and Rho-kinase activity in forearm VSMCs in healthy young men. Our findings suggest that smoking is involved in not only endothelial dysfunction but also activation of Rho-kinase in VSMCs in forearm circulation, and that there is a significant correlation between endothelial function and Rho-kinase activity in VSMCs.
Key Words: smoking • Rho-kinase • endothelial function • vascular smooth muscle cell • healthy young man
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Cigarette smoking is a major risk factor for the development of atherosclerosis. Although several lines of evidence have indicated the mechanisms for endothelial dysfunction by smoking,1,2 the underlying mechanisms are not completely understood. Smoking causes endothelial dysfunction in smokers and passive smokers,3,4 leading to cardiovascular and cerebrovascular complications.5
Recent in vitro and in vivo studies suggested that the Rho-associated kinase (Rho-kinase/ROK/ROCK) family, one of several putative small GTPase Rho effectors, plays major roles in actin cytoskeleton, organization,6,7 smooth muscle contraction,8 and gene expression,9 all of which may be involved in the pathogenesis of atherosclerosis. Results of previous studies have shown that Rho-kinase plays a key role in the contraction of vascular smooth muscle cells (VSMCs). Rho-kinase activates myosin light chain (MLC) kinase (MLCK) by phosphorylation of the myosin-binding subunit (MBS) in MLC phosphatase (MLCPh), leading to contraction of VSMCs.10–12 Smooth muscle dysfunction has been found in subjects with atherosclerosis.13 VSMC dysfunction may be partly attributable to the activation of Rho-kinase in VSMCs. It is thought that Rho-kinase activity also interacts endothelial function in humans. However, there is no information on the relationship between endothelial function and Rho-kinase activity in humans.
To evaluate the effects of smoking on endothelial function and Rho-kinase activity, and to determine the relationship between endothelial function and Rho-kinase activity in humans, we measured vascular responses to acetylcholine (ACh), fasudil, a specific inhibitor of Rho-kinase, and sodium nitroprusside (SNP), a direct vasodilator of VSMCs, in healthy young men.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Subjects
The subjects were 10 healthy young male smokers (mean age 24.9±5.3 years) and 14 healthy age-matched young male nonsmokers (mean age 25.1±4.6 years). All of the subjects were recruited from healthy volunteers. Normal blood pressure was defined as systolic blood pressure of <130 mm Hg and diastolic blood pressure of <80 mm Hg. The results of physical and routine laboratory examinations in all subjects were normal. None of the subjects had a family history of premature cardiovascular disease, and none of the subjects were taking oral contraceptives, antioxidant vitamins, or cardioactive drugs. The study protocol was approved by the ethical committee of Hiroshima University Graduate School of Biomedical Sciences. Informed consent for participation in the study was obtained from all subjects. The definition of smokers was those who fulfilled the prespecified entry criteria: regular smoking history >5 pack years. One pack year was equivalent to 20 cigarettes smoked per day for 1 year. All of the smokers (11.4±13.2 pack years) had a smoking history of >5 years and abstained from smoking for
3 hours before the forearm blood flow (FBF) measurements. We defined nonsmokers as those who had never smoked.
Measurements of FBF
FBF was measured with a mercury-filled Silastic strain-gauge plethysmography (EC-5R; D.E. Hokanson, Inc.), as described previously.14,15
Procedures
The forearm vascular responses to ACh (Daiichi Pharmaceutical Co) were evaluated in 10 smokers and 14 nonsmokers, and fasudil (Asahi Chemical Industries) and SNP (Maluishi Pharmaceutical Co) were evaluated in all subjects. The infusions of ACh, fasudil, and SNP were performed in a randomized fashion. The study began at 8:30 AM with the subjects in the fasting condition. A 23-gauge polyethylene catheter (Hokkow Co) was inserted into the left brachial artery for the infusion of ACh, fasudil, and SNP for the recording of arterial pressure with an AP-641G pressure transducer (Nihon Kohden Co) under local anesthesia (1% lidocaine). Another catheter was inserted into the left deep antecubital vein to obtain blood samples.
After 30 minutes in the supine position, we measured basal FBF and arterial blood pressure. Then, forearm vascular response to ACh, endothelium dependent vasodilator, fasudil, a specific Rho-kinase inhibitor, and SNP, a direct vasodilator of smooth muscle cells, on forearm hemodynamics were measured. ACh (3.75 and 7.5 µg/min), fasudil (3, 10, 30, and 100 µg/min), and SNP (0.75, 1.5, and 3.0 µg/min) were infused intra-arterially for 5 minutes at each dose. Each study proceeded after the FBF returned to baseline.
To determine the coinfusion effect of fasudil on ACh-induced vasodilation, the forearm vascular response to ACh (3.75 and 7.5 µg/min) in combination with fasudil (10 µg/min) was evaluated in 6 smokers and 8 nonsmokers. Furthermore, after a 30-minute rest period, NG-monomethyl-L-arginine (L-NMMA), an NO synthase inhibitor, was infused intra-arterially at a dose of 8 µmol/min for 5 minutes while the basal FBF and arterial blood pressure were recorded and fasudil (3, 10, 30, and 100 µg/min) was administered.
On another day, to determine the effect of fasudil after inhibition of reactive oxygen species (ROS), the forearm vascular responses to fasudil (3, 10, 30, and 100 µg/min) alone and in combination with ascorbic acid (24 mg/min) were evaluated in 7 smokers and 7 nonsmokers.
Analytical Methods
Routine chemical methods were used to determine serum concentrations of total cholesterol, high-density lipoprotein cholesterol, and triglycerides. Serum concentrations of low-density lipoprotein (LDL) were determined using Friedewald’s methods. The concentration of angiotensin II was assayed by radioimmunoassay. The plasma concentrations of norepinephrine were measured by high-performance liquid chromatography.
Statistical Analysis
Results are presented as the means±SD. Values of P<0.05 were considered to indicate statistical significance. The Mann–Whitney U test was used to evaluate differences between current smokers and nonsmokers concerning parameters at baseline. Comparisons between the 2 groups with respect to changes in parameters were performed with adjusted means on an ANCOVA, with baseline data used as the covariates. Comparisons of dose-response curves of parameters during infusion of the drug were analyzed by repeated-measures ANOVA. For the analysis of FBF response to ACh in combination with fasudil and that to fasudil in combination with L-NMMA, the absolute FBF changes from baseline values were used to compare the dose-response curves. Each FBF response to the vasoactive drugs was compared with that in the other group by Bonferroni correction. Spearman’s rank correlation was used to compare the maximal FBF response to ACh with that to fasudil and that to SNP. The data were analyzed using the software package StatView V (SAS Institute Inc.) and Super ANOVA (Abacus Concepts).
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Baseline Clinical Characteristics
The clinical characteristics of the 10 smokers and 14 nonsmokers are summarized in the Table. All of the parameters, including plasma insulin, plasma angiotensin II, norepinephrine, and lipid profiles, were similar in smokers and nonsmokers. Systemic and forearm hemodynamics such as baseline FBF were also similar in the 2 groups.
|
FBF Responses to ACh in Smokers and Nonsmokers
The intra-arterial infusion of ACh significantly increased FBF in a dose-dependent manner in smokers and nonsmokers. The FBF response to ACh was significantly smaller in smokers than in nonsmokers (maximal FBF 12.3±3.3 versus 21.4±6.8 mL/min per 100 mL tissue; P<0.01; Figure 1, top). No significant change was found in arterial blood pressure or heart rate with intra-arterial infusion of ACh in either.
|
; top). *P<0.01 vs smokers. Effects of SNP on FBF in smokers (•) and nonsmokers (
FBF Responses to SNP in Smokers and Nonsmokers
The intra-arterial infusion of SNP significantly increased FBF in a dose-dependent manner in smokers and nonsmokers. There was no significant difference between FBF responses to SNP in the 2 groups (Figure 1, bottom). No significant change was found in arterial blood pressure or heart rate with intra-arterial infusion of SNP in either.
FBF Responses to Fasudil in Smokers and Nonsmokers
The FBF response to fasudil was significantly greater in smokers than in nonsmokers (maximal FBF 23.4±6.1 versus 14.6±5.1 mL/min per 100 mL tissue; P<0.01; Figure 2). No significant change was found in arterial blood pressure or heart rate with intra-arterial infusion of fasudil in either.
|
There was a significant relationship between the maximal FBF response to ACh and that to fasudil (r=–0.67; P<0.01). However, there was no significant relationship between the maximal FBF response to ACh and that to SNP (r=0.08; P=NS) or between the maximal FBF response to fasudil and that to SNP (r=0.28; P=NS).
FBF Responses to ACh Alone and in Combination With Fasudil in Smokers and Nonsmokers
The intra-arterial coinfusion of fasudil significantly augmented FBF response to ACh in smokers (P<0.01; Figure 3) but not in nonsmokers (P=NS; Figure 3). During coinfusion of fasudil, there was no significant difference in ACh-induced vasodilation between the 2 groups. No significant change was found in arterial blood pressure or heart rate with intra-arterial infusion of ACh alone and in combination with fasudil in either.
|
P<0.05 vs before fasudil in nonsmokers. Results are presented as mean±SD. The P value refers to a comparison of time course curves by ANOVA for repeated measurements.
FBF Responses to Fasudil Alone and in Combination With L-NMMA in Smokers and Nonsmokers
The intra-arterial infusion of L-NMMA significantly decreased basal FBF from 7.3±2.8 to 5.1±2.1 mL/min per 100 mL tissue (P<0.05) in smokers and from 8.4±3.0 to 5.1±2.1 mL/min per 100 mL tissue (P<0.05) in nonsmokers. Changes in basal forearm vascular responses to L-NMMA infusion were similar in the 2 groups. There were no significant differences between FBF response to fasudil alone and that in combination with L-NMMA in smokers and in nonsmokers (Figure 4). There was a significant difference between the changes in FBF response to fasudil after coinfusion of L-NMMA in the 2 groups (P<0.01). No significant change was found in arterial blood pressure or heart rate with intra-arterial infusion of fasudil alone and in combination with L-NMMA in either.
|
) and in combination with L-NMMA (
) on FBF in smokers and those of fasudil alone (
FBF Responses to Fasudil Alone and in Combination With Ascorbic Acid in Smokers and Nonsmokers
Ascorbic acid did not alter the FBF response to fasudil in smokers and in nonsmokers (Figure 5). No significant change was found in arterial blood pressure or heart rate with intra-arterial infusion of fasudil alone and in combination with ascorbic acid in either.
|
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
In the present study, we demonstrated that not only endothelial dysfunction but also activated Rho-kinase in VSMCs were found in healthy young male smokers compared with nonsmokers. The results of the present study also showed for the first time that there is a significant correlation between endothelial function and Rho-kinase activity in forearm resistance arteries.
Endothelium-dependent vasodilation was impaired even in healthy young smokers compared with nonsmokers. Our findings are supported by results of previous studies showing that smoking is significantly associated with endothelial dysfunction and cardiovascular disease.3,5,16,17 Structural damage,18 a direct toxic effect,19 a decreased production or bioavailability of endothelial NO,1,2 and a superoxide anion by containing of a large number of free radicals and pro-oxidants in cigarette smoke20 have been proposed as mechanisms of smoking-induced vascular damage.
The main findings of the present study are that the forearm vasodilatory effect evoked by fasudil was greater in smokers than in nonsmokers, whereas SNP-induced vasodilation was similar in the 2 groups, and that there was a significant correlation between the forearm vasodilatory effect evoked by ACh and that by fasudil. Although the precise mechanism of the interaction between endothelial function and Rho-kinase activity remains to be cleared, our results suggest that smoking may contribute to the activation of Rho-kinase in VSMCs as well as endothelial dysfunction. Several lines of evidence have demonstrated that eNOS expression is upregulated by inhibition of Rho-kinase via increase of eNOS mRNA stability and eNOS phosphorylation.21,22 Hernandez-Perera et al23 reported that Rho is required for the basal expression of preproendothelin-1 in vascular endothelial cells, which gives rise to endothelin-1. In addition, several investigators demonstrated an interaction between NO and Rho/Rho-kinase in VSMCs.24,25 Sauzeau et al24 have shown that exogenous NO attenuates RhoA-dependent Ca2+ sensitization of blood vessel contraction by inhibiting RhoA translocation from the cytosol to membrane in VSMCs through activation of the cyclic GMP-dependent kinase pathway. These findings suggest that endothelial dysfunction may result in Rho-kinase activation in VSMCs through a decrease in NO production from the endothelium, and that activated Rho-kinase may inhibit eNOS expression in the endothelium. Consequently, endothelial dysfunction and activation of Rho-kinase in VSMCs may be evoked by smoking.
Recent studies have shown that Rho-kinase plays important roles in various cellular functions, including vascular smooth muscle contraction.8,11,12,26 Uehata et al27 reported that systemic administration of a Rho-kinase inhibitor, Y-27632, induced significant and persistent decreases in blood pressure in hypertensive rat models. In clinical studies, several investigators reported that hypertension, stable angina pectoris, and coronary vasospasm are associated with activation of Rho-kinase.28–30 These findings suggest that activation of Rho-kinase in VSMCs is involved in the development and progression of the atherosclerotic process. Furthermore, recent studies demonstrated the partial contribution of Rho-kinase to VSMC contraction. VSMC contraction is modulated in a dual manner by MLCK and MLCPh, so that the phosphorylation of MBS on MLCPh by Rho-kinase results in the phosphorylation of MLC and subsequent contraction of VSMCs.31 Moreover, MLC diphosphorylation as well as MLC monophosphorylation were found in impaired VSMCs.26,32 It is postulated that smoking is associated with Rho-kinase activity.
In the present study, we evaluated endothelial function by using ACh, which is well established as an endothelial dependent vasodilator,14 and we evaluated Rho-kinase activity in VSMCs by using fasudil, a Rho-kinase inhibitor.15 Fasudil, which is currently used for prevention and treatment of cerebral vasospasm after subarachnoid hemorrhage, has been shown recently to be a potent and specific inhibitor of Rho-kinase.33,34 In addition, fasudil is used for assessment of Rho-kinase activity in humans.28–30 However, we cannot deny the possibility that fasudil, especially at high doses, has nonspecific effects on vasculature.
In the present study, L-NMMA did not alter the FBF response to fasudil in smokers or nonsmokers. Interestingly, coinfusion of fasudil significantly augmented the FBF response to ACh in smokers but not in nonsmokers. These results may be attributable to decreased Ca2+ sensitivity by inhibition of Rho-kinase in VSMCs in smokers. These findings support our hypothesis that Rho-kinase in VSMCs is activated in smokers compared with nonsmokers, although it remains to be clarified whether endogenous NO inhibits Rho-kinase activity in humans. Of additional interest, there was no significant difference between FBF response to ACh in combination with fasudil in smokers and that in nonsmokers in the present study. This may be explained by a decrease in Ca2+ sensitivity attributable to inhibition of Rho-kinase in VSMCs and by an increase in phosphorylation of eNOS attributable to inhibition of Rho-kinase in endothelial cells in smokers.22 Wolfrum et al35 demonstrated in a rat model of myocardial infarction that acute administration of fasudil leads to rapid activation of eNOS through the phosphatidylinositol 3-kinase/Akt pathway, resulting in increased NO production and subsequent cardiovascular protection. On the other hand, several investigators have shown that inhibition of Rho-kinase upregulates eNOS expression through increase in eNOS mRNA stability and eNOS phosphorylation.23,35 We cannot deny the possibility that fasudil improves endothelial function via upregulation of eNOS expression in smokers.
Recently, Higashi et al36 demonstrated that Rho-kinase is substantially involved in production of ROS through NAD(P)H oxidase upregulation. Moreover, several investigators have shown a possible interaction between Rho/Rho-kinase and ROS.37,38 In the present study, coinfusion of antioxidant ascorbic acid had no effect on FBF response to fasudil in smokers or nonsmokers. It is unlikely that ROS has effects on Rho-kinase activity in healthy young male smokers.
Several methods have been used to assess endothelial function in humans. Recently, several investigators, including us, evaluated the effects of intra-arterial infusion of NO agonists, such as ACh, methacholine, and bradykinin, and the effects of intra-arterial infusion of NO antagonists on FBF. The responses to intra-arterial infusion of vasoactive agents should be considered the gold standard for assessing endothelial function because the use of agonists to stimulate NO release and the use of antagonists of NO allow us to draw more specific conclusions concerning the role of basal and stimulated NO release. Measurement of flow-mediated vasodilation (FMD) in the brachial artery using ultrasound also reflects NO production well. It is accepted that measurement of FBF responses to vasoactive agents is an index of resistance artery endothelial function and that measurement of FMD is an index of conduit artery endothelial function. Both measurements of FBF responses to vasoactive agents and FMD would enable more specific conclusions concerning the relationship between Rho-kinase activity and endothelial function to be drawn. Unfortunately, we were not able to perform measurement of FMD as an index of conduit artery endothelial function in the present study.
Endothelial dysfunction and activation of Rho-kinase may play a critical role in the pathogenesis of atherosclerosis in smokers, leading to cardiovascular and cerebrovascular complications. Further studies on the mechanisms underlying the interaction between endothelial function and Rho-kinase, not only in smokers but also in other subjects who have cardiovascular risk factors such as hypercholesterolemia and diabetes mellitus, are awaited for future therapeutic benefits.
|
Acknowledgments |
|---|
This study was supported in part by a grant-in-aid for scientific research from the Ministry of Education, Science and Culture of Japan; a Japan Heart Foundation grant for research on hypertension and vascular metabolism; and a grant from the Research Foundation for Community Medicine. The authors thank the Research Foundation for Community Medicine.
Received January 13, 2005; accepted September 26, 2005.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Morrow JD, Frei B, Longmire AW, Gaziano JM, Lynch SM, Shyr Y, Strauss WE, Oates JA, Roberts LJ II. Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers—smoking as a cause of oxidative damage. N Engl J Med. 1995; 332: 1198–1203.
2. Barua RS, Ambrose JA, Eales-Reynolds LJ, DeVoe MC, Zervas JG, Saha DC. Dysfunctional endothelial nitric oxide biosynthesis in healthy smokers with impaired endothelium-dependent vasodilatation. Circulation. 2001; 104: 1905–1910.
3. Celermajer DS, Sorensen KE, Georgakopoulos D, Bull C, Thomas O, Robinson J, Deanfield JE. Cigarette smoking is associated with dose-related and potentially reversible impairment of endothelium-dependent dilation in healthy young adults. Circulation. 1993; 88: 2149–2155.
4. Celermajer DS, Adams MR, Clarkson P, Robinson J, McCredie R, Donald A, Deanfield JE. Passive smoking and impaired endothelium-dependent arterial dilation in healthy young adults. N Engl J Med. 1996; 334: 150–154.
5. Holbrook JH, Grundy SM, Hennekens CH, Kannel WB, Strong JP. Cigarette smoking and cardiovascular disease. A statement for health professionals by a task force appointed by the steering committee of the American Heart Association. Circulation. 1984; 70: 1114A–1117A.
6. Amano M, Chihara K, Kimura K, Fukata Y, Nakamura N, Matsuura Y, Kaibuchi K. Formation of actin stress fibers and focal adhesions enhanced by Rho-kinase. Science. 1997; 275: 1308–1311.
7. Hall A. Rho GTPases and the actin cytoskeleton. Science. 1998; 279: 509–514.
8. Kaibuchi K, Kuroda S, Amano M. Regulation of the cytoskeleton and cell adhesion by the Rho family GTPases in mammalian cells. Annu Rev Biochem. 1999; 68: 459–486.[CrossRef][Medline] [Order article via Infotrieve]
9. Chihara K, Amano M, Nakamura N, Yano T, Shibata M, Tokui T, Ichikawa H, Ikebe R, Ikebe M, Kaibuchi K. Cytoskeletal rearrangements and transcriptional activation of c-fos serum response element by Rho-kinase. J Biol Chem. 1997; 272: 25121–25127.
10. Kimura K, Ito M, Amano M, Chihara K, Fukata Y, Nakafuku M, Yamamori B, Feng J, Nakano T, Okawa K, Iwamatsu A, Kaibuchi K. Regulation of myosin phosphatase by Rho and Rho-associated kinase (Rho kinase). Science. 1996; 273: 245–248.[Abstract]
11. Kureishi Y, Kobayashi S, Amano M, Kimura K, Kanaide H, Nakano T, Kaibuchi K, Ito M. Rho-associated kinase directly induces smooth muscle contraction through myosin light chain phosphorylation. J Biol Chem. 1997; 272: 12257–12260.
12. Somlyo AP, Somlyo AV. Signal transduction and regulation in smooth muscle. Nature. 1994; 372: 231–236.[CrossRef][Medline] [Order article via Infotrieve]
13. Adams MR, Robinson J, McCredie R, Seale JP, Sorensen KE, Deanfield JE, Celermajer DS. Smooth muscle dysfunction occurs independently of impaired endothelium-dependent dilation in adults at risk of atherosclerosis. J Am Coll Cardiol. 1998; 32: 123–127.
14. Higashi Y, Sasaki S, Nakagawa K, Matsuura H, Oshima T, Chayama K. Endothelial function and oxidative stress in renovascular hypertension. N Engl J Med. 2002; 346: 1954–1962.
15. Noma K, Higashi Y, Jitsuiki D, Hara K, Kimura M, Nakagawa K, Goto C, Oshima T, Yoshizumi M, Chayama K. Smoking activates rho-kinase in smooth muscle cells of forearm vasculature in humans. Hypertension. 2003; 41: 1102–1105.
16. Kimura M, Higashi Y, Hara K, Noma K, Sasaki S, Nakagawa K, Goto C, Oshima T, Yoshizumi M, Chayama K. PDE5 inhibitor sildenafil citrate augments endothelium-dependent vasodilation in smokers. Hypertension. 2003; 41: 1106–1110.
17. Wang XL, Sim AS, Badenhop RF, McCredie RM, Wilcken DE. A smoking-dependent risk of coronary artery disease associated with a polymorphism of the endothelial nitric oxide synthase gene. Nat Med. 1996; 2: 41–45.[CrossRef][Medline] [Order article via Infotrieve]
18. Booyse FM, Osikowicz G, Quaarfoot AJ. Effect of chronic oral consumption of nicotine on the rabbit aortic endothelium. Am J Pathol. 1981; 102: 229–238.[Abstract]
19. Asmussen G, Kjeldsen K. Intimal ultrastructure of human umbilical arteries: observation on arteries from newborn children of smoking and nonsmoking mothers. Circ Res. 1975; 36: 579–589.
20. Simon BC, Cunningham LD, Cohen RA. Oxidized low density lipoproteins cause contraction and inhibit endothelium-dependent relaxation in the pig coronary artery. J Clin Invest. 1990; 86: 75–79.
21. Takemoto M, Sun J, Hiroki J, Shimokawa H, Liao JK. Rho-kinase mediates hypoxia-induced downregulation of endothelial nitric oxide synthase. Circulation. 2002; 106: 57–62.
22. Ming XF, Viswambharan H, Barandier C, Ruffieux J, Kaibuchi K, Rusconi S, Yang Z. Rho GTPase/Rho kinase negatively regulates endothelial nitric oxide synthase phosphorylation through the inhibition of protein kinase B/Akt in human endothelial cells. Mol Cell Biol. 2002; 22: 8467–8477.
23. Hernandez-Perera O, Perez-Sala D, Soria E, Lamas S. Involvement of Rho GTPases in the transcriptional inhibition of preproendothelin-1 gene expression by simvastatin in vascular endothelial cells. Circ Res. 2000; 87: 616–622.
24. Sauzeau V, Le Jeune H, Cario-Toumaniantz C, Smolenski A, Lohmann SM, Bertoglio J, Chardin P, Pacaud P, Loirand G. Cyclic GMP-dependent protein kinase signaling pathway inhibits RhoA-induced Ca2+ sensitization of contraction in vascular smooth muscle. J Biol Chem. 2000; 275: 21722–21729.
25. Sawada N, Itoh H, Yamashita J, Doi K, Inoue M, Masatsugu K, Fukunaga Y, Sakaguchi S, Sone M, Yamahara K, Yurugi T, Nakao K. cGMP-dependent protein kinase phosphorylates and inactivates RhoA. Biochem Biophys Res Commun. 2001; 280: 798–805.[CrossRef][Medline] [Order article via Infotrieve]
26. Nagumo H, Sasaki Y, Ono Y, Okamato H, Seto M, Takuwa Y. Rho kinase inhibitor HA-1077 prevents Rho-mediated myosin phosphatase inhibition in smooth muscle cells. Am J Physiol Cell Physiol. 2000; 278: C57–C65.
27. Uehata M, Ishizaki T, Satoh H, Ono T, Kawahara T, Morishita T, Tamakawa H, Yamagami K, Inui J, Maekawa M, Narumiya S. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature. 1997; 389: 990–994.[CrossRef][Medline] [Order article via Infotrieve]
28. Masumoto A, Hirooka Y, Shimokawa H, Hironaga K, Setoguchi S, Takeshita A. Possible involvement of Rho-kinase in the pathogenesis of hypertension in humans. Hypertension. 2001; 38: 1307–1310.
29. Shimokawa H, Hiramori K, Iinuma H, Hosoda S, Kishida H, Osada H, Katagiri T, Yamauchi K, Yui Y, Minamino T, Nakashima M, Kato K. Anti-anginal effect of fasudil, a Rho-kinase inhibitor, in patients with stable effort angina: a multicenter study. J Cardiovasc Pharmacol. 2002; 40: 751–761.[CrossRef][Medline] [Order article via Infotrieve]
30. Masumoto A, Mohri M, Shimokawa H, Urakami L, Usui M, Takeshita A. Suppression of coronary artery spasm by the Rho-kinase inhibitor fasudil in patients with vasospastic angina. Circulation. 2002; 105: 1545–1547.
31. Somlyo AP, Somlyo AV. Signal transduction by G-proteins, rho-kinase and protein phosphatase to smooth muscle and non-muscle myosin II. J Physiol. 2000; 522: 177–185.
32. Katsumata N, Shimokawa H, Seto M, Kozai T, Yamawaki T, Kuwata K, Egashira K, Ikegaki I, Asano T, Sasaki Y, Takeshita A. Enhanced myosin light chain phosphorylations as a central mechanism for coronary artery spasm in a swine model with interleukin-1beta. Circulation. 1997; 96: 4357–4363.
33. Davies SP, Reddy H, Caivano M, Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000; 351: 95–105.[CrossRef][Medline] [Order article via Infotrieve]
34. Shimokawa H, Morishige K, Miyata K, Kandabashi T, Eto Y, Ikegaki I, Asano T, Kaibuchi K, Takeshita A. Long-term inhibition of Rho-kinase induces a regression of arteriosclerotic coronary lesions in a porcine model in vivo. Cardiovasc Res. 2001; 51: 169–177.
35. Wolfrum S, Dendorfer A, Rikitake Y, Stalker TJ, Gong Y, Scalia R, Dominiak P, Liao JK. Inhibition of Rho-kinase leads to rapid activation of phosphatidylinositol 3-kinase/protein kinase Akt and cardiovascular protection. Arterioscler Thromb Vasc Biol. 2004; 24: 1842–1847.
36. Higashi M, Shimokawa H, Hattori T, Hiroki J, Mukai Y, Morikawa K, Ichiki T, Takahashi S, Takeshita A. Long-term inhibition of Rho-kinase suppresses angiotensin II-induced cardiovascular hypertrophy in rats in vivo. Circ Res. 2003; 93: 767–775.
37. Jin L, Ying Z, Webb RC. Activation of Rho/Rho kinase signaling pathway by reactive oxygen species in rat aorta. Am J Physiol Heart Circ Physiol. 2004; 287: H1495–H1500.
38. Bailey SR, Mitra S, Flavahan S, Flavahan NA. Reactive oxygen species from smooth muscle mitochondria initiate cold-induced constriction of cutaneous arteries. Am J Physiol Heart Circ Physiol. 2005; 289: H243–H250.
This article has been cited by other articles:
 |
|
 |
|
  T. R. Richens, D. J. Linderman, S. A. Horstmann, C. Lambert, Y.-Q. Xiao, R. L. Keith, D. M. Boe, K. Morimoto, R. P. Bowler, B. J. Day, et al. Cigarette Smoke Impairs Clearance of Apoptotic Cells through Oxidant-dependent Activation of RhoA Am. J. Respir. Crit. Care Med., June 1, 2009; 179(11): 1011 - 1021. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Sumiyoshi, H. Mokuno, T. Iesaki, K. Shimada, T. Miyazaki, A. Kume, T. Kiyanagi, K. Kuremoto, Y. Watanabe, N. Tada, et al. Deletion of the Fc receptors {gamma} chain preserves endothelial function affected by hypercholesterolaemia in mice fed on a high-fat diet Cardiovasc Res, December 1, 2008; 80(3): 463 - 470. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Iida, M. Iida, M. Takenaka, N. Fukuoka, and S. Dohi Rho-kinase inhibitor and Nicotinamide Adenine Dinucleotide PHosphate oxidase inhibitor prevent impairment of endothelium-dependent cerebral vasodilation by acute cigarette smoking in rats Journal of Renin-Angiotensin-Aldosterone System, June 1, 2008; 9(2): 89 - 94. [Abstract] [PDF]
|
|
|
|
 |
|
 S. de Ferranti and D. Mozaffarian The Perfect Storm: Obesity, Adipocyte Dysfunction, and Metabolic Consequences Clin. Chem., June 1, 2008; 54(6): 945 - 955. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. L. Ding and F. B. Hu Smoking and Type 2 Diabetes: Underrecognized Risks and Disease Burden JAMA, December 12, 2007; 298(22): 2675 - 2676. [Full Text] [PDF]
|
|
|
|
 |
|
 E. Bussemaker, F. Pistrosch, S. Forster, K. Herbrig, P. Gross, J. Passauer, and R. P. Brandes Rho kinase contributes to basal vascular tone in humans: role of endothelium-derived nitric oxide Am J Physiol Heart Circ Physiol, July 1, 2007; 293(1): H541 - H547. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P.-Y. Liu, J.-H. Chen, L.-J. Lin, and J. K. Liao Increased Rho Kinase Activity in a Taiwanese Population With Metabolic Syndrome J. Am. Coll. Cardiol., April 17, 2007; 49(15): 1619 - 1624. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. S. Thompson-Torgerson, L. A. Holowatz, N. A. Flavahan, and W. L. Kenney Cold-induced cutaneous vasoconstriction is mediated by Rho kinase in vivo in human skin Am J Physiol Heart Circ Physiol, April 1, 2007; 292(4): H1700 - H1705. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Noma, C. Goto, K. Nishioka, D. Jitsuiki, T. Umemura, K. Ueda, M. Kimura, K. Nakagawa, T. Oshima, K. Chayama, et al. Roles of Rho-Associated Kinase and Oxidative Stress in the Pathogenesis of Aortic Stiffness J. Am. Coll. Cardiol., February 13, 2007; 49(6): 698 - 705. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. S. Waring, J. A. McKnight, D. J. Webb, and S. R.J. Maxwell Uric Acid Restores Endothelial Function in Patients With Type 1 Diabetes and Regular Smokers Diabetes, November 1, 2006; 55(11): 3127 - 3132. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Chrissobolis and C. G. Sobey Recent Evidence for an Involvement of Rho-Kinase in Cerebral Vascular Disease Stroke, August 1, 2006; 37(8): 2174 - 2180. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||